Navigation Links
Richard W. Schulte of Wright & Schulte LLC: a Tireless Fighter for Victims of Generic Drug Labeling Practices
Date:4/18/2013

Dayton, OH (PRWEB) April 18, 2013

Richard W. Schulte, a partner with the experienced drug injury firm of Wright & Schulte LLC, continues his fight on behalf of victims of generic drug injuries, the Firm reports. On March 14th, the Sixth Circuit Court of Appeals ruled that a woman being represented by Richard Schulte could proceed with her state failure to warn claim against Pliva, Inc. for injuries she allegedly suffered due to the company’s generic version of the drug metoclopramide. According to Wright & Schulte, numerous courts have dismissed state law failure to warn claims filed against generic drug makers, following the U.S. Supreme Court’s 2011 decision in Pliva vs. Mensing, which found that such claims were pre-empted by federal law. (Pliva, Inc. v. Mensing 131 S. Ct. 2567) The recent Sixth Circuit decision in the generic metoclopromide case creates a narrow exception to the pre-emption defense established by the Mensing decision. (Fulgenzi v. Pliva, Inc. Case No. 12 - 3504, 6th Cir.)

According to the Sixth Circuit ruling, the client represented by Richard Schulte allegedly suffered tardive dyskinesia, a repetitive movement disorder, as a result of using Pliva’s metoclopromide between 2004 and 2007 to treat her gastric reflux. In 2004, the U.S. Food & Drug Administration (FDA) ordered the maker of Reglan, the name-brand version of metoclopramide, to update the drug’s label to warn that it should not be used for longer than 12 weeks because of its association with tardive dyskinesia. However, Pliva did not follow suit and update the label of its generic metoclopramide to include the same warning.

While the generic metoclopramide lawsuit was filed before the U.S. Supreme Court issued its ruling in Pliva vs. Mensing, the claim was dismissed by a lower court in the wake of that decision. In an appeal to the Sixth Circuit, Richard Schulte of Wrigth & Schulte LLC argued that according to the federal rule of sameness, Pliva was obligated to update the warning label of the generic drug once the label on the brand name version was modified. In a unanimous decision, a three-judge panel of the Sixth Circuit agreed, finding that the company could have updated its label without violating its duty of sameness. According to Wright & Schulte, the Sixth Circuit ruling means that generic drug makers can no longer simply rely on the Mensing decision’s preemption defense to avoid liability for injuries allegedly caused by one of their products, but must be able to show they were diligent and timely in keeping their labels up-to-date.

This is not the first time Richard Schulte has taken up the fight on behalf of individuals allegedly injured by generic drugs. As Co-Lead Counsel in a multidistrict litigation underway in U.S. District Court, Eastern District of Kentucky, he is currently representing hundreds of people allegedly injured by the drug Propoxyphene, sold generically and under the brand names Darvon and Darvocet. On February 20th, Richard Schulte, together with his Co-Lead Counsel and the Center for Constitutional Litigation, filed an Amicus Brief in an important generic drug case known as Mutual Pharmaceutical Co. v. Bartlett that is currently before the U.S. Supreme Court. The Brief, which was filed on behalf of all persons allegedly injured by Propoxyphene, urged the High Court to uphold a lower court ruling allowing a jury award levied against a generic drug maker in a state law design defect claim to stand. According to the Brief, the Supreme Court’s ultimate decision in the Bartlett case will directly affect generic drug claims pending in the federal Propoxyphene litigation. (Mutual Pharmaceutical Co. v. Bartlett, 12-142.)

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced drug injury law firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged, and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free drug injury lawsuit evaluations are available through yourlegalhelp.com, or call 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795

Read the full story at http://www.prweb.com/releases/2013/4/prweb10592100.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Author, Speaker Richard London Battles Parkinson’s with an Active Lifestyle and the Desire to Give Back
2. ASH honors David Ginsburg, M.D., and Richard Aster, M.D., with 2012 Henry M. Stratton Medal
3. LA BioMeds Dr. Richard Casaburi investigates causes of COPD
4. Richard Mayeux, M.D., M.S., elected Fellow of AAAS
5. Stealth Attraction: Review of Richard La Ruina's Attraction Training Course Released By PUABooks.net
6. Jacksonville Periodontist, Dr. Richard E. Aguila, Now Fixes High Gum Lines with Crown Lengthening Procedures for His Florida Patients with Excessive Gums Showing
7. Skechers Injury Lawsuit Update: Richard W. Schulte, Partner with Wright & Schulte LLC, Appointed to Plaintiffs’ Steering Committee in California Skechers Toning Shoes Litigation
8. Ms. Viola Richardson, Jersey City Councilwoman-at-Large, Participates in the Annual Steve Sobel SYC 2013 Fencing Competition
9. Wright & Schulte LLC Encourages Drivers to Review Safe Winter Driving Tips
10. Wright & Schulte File Skechers Lawsuit on Behalf of Ohio Woman Who Fell, Suffered Broken Wrist Allegedly Due to Use of Skechers Shape-Ups
11. Wright & Schulte LLC Files Transvaginal Mesh Lawsuit on Behalf of Woman Allegedly Injured by Align Urethral Support System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of ... Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who ... this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program ...
(Date:5/27/2016)... ... 27, 2016 , ... With over 60 percent of acute stroke survivors being ... product to aid in the rehabilitation process has steadily increased. Ekso Bionics had been ... hemiplegia due to stroke. , Ekso Bionics has now received clearance from the U.S. ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... ... , ... Aimed at nurses and employees in the health care world, this ... the nursing and health care industry. It also provides insight to the developing trends ... , As the nursing industry is coming out of one of the biggest recessions ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... Neurology and Orphan Diseases, today announced that President & CEO ... conferences: SeeThru Equity MicroCap Conference   ... City , NY When: Tuesday, May 31 st ... Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... -- According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - ... valued at US$ 5.89 Bn in 2014 and is anticipated ... 2023 to reach US$ 7.99 Bn in 2023. ... free drug delivery devices and the market is estimated based ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
Breaking Medicine Technology: